A Phase 3 interventional study of Insulin Peglispro and Insulin Glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing LY2605541 in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. LY2605541 · Diabetes Mellitus, Type 2.
Among the 10 studies testing LY2605541 in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 9th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 10 studies testing LY2605541 in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 339 across the 10 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 160th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2014, is one of 85 in phase 3, and was the 109th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing LY2605541 in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes. Participants will be treated with study insulin daily, in two 4-week study periods. Each participant will receive insulin peglispro during one treatment period and insulin glargine during the other treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have been treated with stable doses of insulin for at least 30 days before screening with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
Drug: Insulin Peglispro
Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
Drug: Insulin Glargine
Administered SQ
Also known as: LY2605541
Administered SQ
Percentage of Participants With Clinically Significant Hypoglycemia
The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 milligrams per deciliter (mg/dL) (3.0 millimole per liter \[mmol/L\]) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.
Time frame: Predose to 84 Hours Post Double Dose
Percentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose
The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 mg/dL (3.0 mmol/L) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.
Time frame: Predose to 12 Hours Post Double Dose
Percentage of Participants With Hypoglycemia
The percentage was calculated by dividing the number of participants with hypoglycemia events defined as blood glucose ≤70 mg/dL (3.9 mmol/L) by the total number of participants analyzed, multiplied by 100.
Time frame: Predose to 12 Hours Post Double Dose and 84 Hours Post Double Dose
Nadir Glucose
Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
Time frame: Predose to 84 Hours Post Double Dose
Time to the Nadir Glucose
Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). The average time was calculated by dividing the sum of time from double dose to the nadir glucose for participants with blood glucose ≤70 mg/dL (3.9 mmol/L) by the number of participants with blood glucose ≤70 mg/dL (3.9 mmol/L) during the first 84 hours after the double dose.
Time frame: Predose to 84 Hours Post Double Dose
Duration of Glucose ≤70 mg/dL
The duration in minutes of each hypoglycemia episode with glucose ≤70 mg/dL (3.9 mmol/L) was calculated from start time to end time. The duration for a participant was the sum of the durations over the multiple hypoglycemia episodes. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
Time frame: Predose to 84 Hours Post Double Dose
Fasting Blood Glucose
Fasting blood glucose (FBG) was measured by self-monitored blood glucose. LS means were calculated by MMRM analysis with fixed effects of treatment, dosing day, sequence, period, interaction of treatment and dosing day, baseline basal insulin dose stratification factor, and baseline FBG.
Time frame: Day 1, Day 2, and Day 3 Following Double Dose
Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC)
Glucose AUC within 3 hours after each meal assessed by the AUC of glucose from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
Time frame: Preprandial to 3 Hours Postprandial during the day following the standard dose
Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC) Excursion
Glucose AUC excursion within 3 hours after each meal assessed by the AUC of adjusted glucose (= observed glucose - preprandial glucose) from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
Time frame: Preprandial to 3 Hours Postprandial during the day following the standard dose
Beta Cell Function
Beta cell function assessed by the change between pre meal tolerance test and 30 minutes post meal tolerance test in C-peptide corrected insulin/Glucose (ΔC-peptide corrected insulin/ΔGlucose). LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
Time frame: 0-30 minutes during the meal tolerance test on the day following the standard dose
| Milestone | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro |
|---|---|---|
| Started | 34 | 34 |
| Received at least one dose of study drug | 34 | 34 |
| Completed | 33 | 30 |
| Not completed | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro |
|---|---|---|
| Started | 33 | 30 |
| Completed | 31 | 29 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 2 | 0 |
The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 milligrams per deciliter (mg/dL) (3.0 millimole per liter \[mmol/L\]) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.
| percentage of participants | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Percentage of Participants With Clinically Significant Hypoglycemia | 6.6 | 35.5 |
The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 mg/dL (3.0 mmol/L) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.
| percentage of participants | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Percentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose | 1.6 | 22.6 |
The percentage was calculated by dividing the number of participants with hypoglycemia events defined as blood glucose ≤70 mg/dL (3.9 mmol/L) by the total number of participants analyzed, multiplied by 100.
| percentage of participants | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| 12 Hours Post Double Dose | 19.7 | 64.5 |
| 84 Hours Post Double Dose | 42.6 | 82.3 |
Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
| mg/dL | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Nadir Glucose | 61.70 ± 1.36 | 55.93 ± 0.97 |
Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). The average time was calculated by dividing the sum of time from double dose to the nadir glucose for participants with blood glucose ≤70 mg/dL (3.9 mmol/L) by the number of participants with blood glucose ≤70 mg/dL (3.9 mmol/L) during the first 84 hours after the double dose.
| hours | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Time to the Nadir Glucose | 35.92 ± 26.37 | 28.15 ± 23.46 |
The duration in minutes of each hypoglycemia episode with glucose ≤70 mg/dL (3.9 mmol/L) was calculated from start time to end time. The duration for a participant was the sum of the durations over the multiple hypoglycemia episodes. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
| Minutes per participant | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Duration of Glucose ≤70 mg/dL | 95.28 ± 37.57 | 362.26 ± 37.26 |
Fasting blood glucose (FBG) was measured by self-monitored blood glucose. LS means were calculated by MMRM analysis with fixed effects of treatment, dosing day, sequence, period, interaction of treatment and dosing day, baseline basal insulin dose stratification factor, and baseline FBG.
| mg/dL | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Day 1 | 102.03 ± 2.90 | 85.61 ± 2.87 |
| Day 2 | 100.94 ± 2.92 | 86.16 ± 2.91 |
| Day 3 | 102.18 ± 2.99 | 86.27 ± 3.00 |
Glucose AUC within 3 hours after each meal assessed by the AUC of glucose from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
| mg/dL*h | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Breakfast | 633.50 ± 15.59 | 568.64 ± 15.51 |
| Lunch | 566.00 ± 19.92 | 568.20 ± 19.84 |
| Dinner | 564.68 ± 15.95 | 577.46 ± 15.95 |
Glucose AUC excursion within 3 hours after each meal assessed by the AUC of adjusted glucose (= observed glucose - preprandial glucose) from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
| mg/dL*h | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Breakfast | 266.33 ± 12.04 | 270.32 ± 11.98 |
| Lunch | -2.38 ± 11.42 | 36.92 ± 11.34 |
| Dinner | 134.40 ± 10.20 | 150.23 ± 10.20 |
Beta cell function assessed by the change between pre meal tolerance test and 30 minutes post meal tolerance test in C-peptide corrected insulin/Glucose (ΔC-peptide corrected insulin/ΔGlucose). LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.
| mmol/L | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Beta Cell Function | 88.65 ± 8.43 | 103.62 ± 8.32 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Peglispro | — | 2/64 (3.1%) | 31/64 (48.4%) |
| Insulin Glargine | — | 1/67 (1.5%) | 26/67 (38.8%) |
| Event | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| Gastritis erosiveGastrointestinal disorders | 1/64 | 0/67 |
| Otitis mediaInfections and infestations | 1/64 | 1/67 |
| Event | Insulin Peglispro | Insulin Glargine |
|---|---|---|
| HeadacheNervous system disorders | 11/64 | 7/67 |
| NasopharyngitisInfections and infestations | 5/64 | 6/67 |
| Back painMusculoskeletal and connective tissue disorders | 4/64 | 4/67 |
| Abdominal painGastrointestinal disorders | 3/64 | 1/67 |
| NauseaGastrointestinal disorders | 3/64 | 0/67 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/64 | 1/67 |
| EcchymosisSkin and subcutaneous tissue disorders | 2/64 | 3/67 |
| VertigoEar and labyrinth disorders | 2/64 | 1/67 |
| VomitingGastrointestinal disorders | 2/64 | 0/67 |
| DiarrhoeaGastrointestinal disorders | 1/64 | 2/67 |
All randomized participants
| Age, Continuous(years) | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro | Total |
|---|---|---|---|
| Mean | 57.82 ± 8.06 | 57.74 ± 5.86 | 57.78 ± 6.99 |
| Sex: Female, Male(Participants) | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro | Total |
|---|---|---|---|
| Female | 10 | 10 | 20 |
| Male | 24 | 24 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 30 | 29 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 32 | 34 | 66 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Insulin Peglispro/Insulin Glargine | Insulin Glargine/Insulin Peglispro | Total |
|---|---|---|---|
| United States | 5 | 5 | 10 |
| Germany | 29 | 29 | 58 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of May 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 2 years 9 months after primary completion. A results delay was requested in Sep 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LY2605541 · Insulin Glargine